A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

August 31, 2018

Conditions
Malignant Melanoma
Interventions
BIOLOGICAL

HF10 plus Ipilimumab

Patients will receive the dose of 1 x 10\^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).

Trial Locations (8)

17033

Clinical Site, Hershey

18015

Clinical Site, Bethlehem

30322

Clinical Site, Atlanta

75230

Clinical Site, Dallas

77030

Clinical Site, Houston

84112

Clinical Site, Salt Lake City

94115

Clinical Site, San Francisco

97239

Clinical Site, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Theradex

INDUSTRY

lead

Takara Bio Inc.

INDUSTRY